Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
India Glycols Ltd

| Q2 & H1 FY 26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤18th Nov 25

Summary : India Glycols reported strong Q2 and H1 FY26 growth, driven by Biofuels and Potable Spirits, with strategic debt reduction and expansion into premium products and new chemicals, despite global market pressures.

Management Perspective positive : So, overall, we have seen a good strong growth and net revenue growth for the business. And we have also reported an EBITDA margin, which has a healthy upside of 216 basis points, while the absolute EBITDA has grown by 33%. I am quite confident about the strong pipeline that we have. That business quite small is doing well, with very strong partnerships starting to merge with significant players like BASF, Newpark, Dow, etc.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 gross revenues increased 13% to INR 2,412 crores; net revenue up 14% to INR 1,092 crores.
  2. Q2 FY26 EBITDA grew 33% to INR 160 crores, with margins expanding from 12.4% to 14.6%.
  3. H1 FY26 gross revenues rose 11% to INR 4,916 crores; net revenue up 11% to INR 2,133 crores.
  4. Biofuels sales surged 63% in Q2 to INR 423 crores, and 55% in H1 to INR 770 crores.
  5. Potable Spirits sales increased 24% in Q2 to INR 338 crores, and 23% in H1 to INR 680 crores.

Future Growth Prospects

  1. Government aims to increase ethanol blending beyond 20% to 27% post-October 2026.
  2. Company is developing new performance chemicals and bio-based amines with strong partnerships.
  3. Expanding IMFL market presence in Kerala and securing Canteen Services Department approvals.
  4. Focusing on branded nutraceuticals with US FDA approval and global certifications.
  5. Anticipate improved raw material availability and favorable excise policies for liquor business.

Management Insights

  1. Reported strong Q2 and H1 FY26 performance driven by Biofuels and Potable Spirits segments.
  2. EBITDA margins have shown healthy expansion across key business segments.
  3. Strategic debt reduction planned using preferential allotment funds to lower finance costs.
  4. Committed to investing incrementally in new technologies and value-added chemicals.
  5. Confident in the long-term growth and quality improvement of the business.

Signs of Skepticism

  1. Management found it difficult to quantify the exact tariff impact on JV and direct sales.
  2. The growth in premium liquor brands is acknowledged as a slow, gradual process.
  3. Specific numbers for NSU segment contribution were not provided, only broad expectations of doubling.
  4. Uncertainty regarding future government clarification on ethanol blending beyond 20%.

Risk Factors

  1. Global crude oil price volatility impacts petrochemical-based alternatives and margins.
  2. US tariffs of 50% have negatively affected joint venture and direct product sales.
  3. Excess ethanol capacity in the industry may lead to price softening.
  4. Competition and supply chain disruptions (e.g., Gloriosa seed) pressure Ennature Biopharma segment.
  5. Establishing premium liquor brands is a slow process requiring patience.

Good To Know

  1. Company plans to reduce INR 1,400 crores long-term debt by INR 467 crores from preferential allotment and INR 180 crores from internal accruals.
  2. Post-demerger, debt will be split between India Glycols (INR 600 crores) and IGL Spirits (INR 800 crores).
  3. Average cost of long-term debt is 10%, working capital at 9.25%, expected to reduce by INR 60-70 crores annually.
  4. Amrut partnership is exclusive for certain brands, with IGL handling manufacturing, sales, and investment.
  5. The company is evaluating advanced biofuels like SAF and green chemistries for future growth vectors.

Key Drivers

  1. Ethanol blending program expansion to 27%.
  2. New performance chemicals gaining traction.
  3. Debt reduction to lower finance costs.
  4. Premium liquor brand market expansion.

Key Analyst Discussions

Competitive Environment

  1. Asked about factors leading to margin improvement in the Chemicals segment despite revenue decline.
  2. Inquired about the impact of low-cost production by new facilities on nicotine sales.
  3. Questioned the strategy for the Ennature Bio Pharma segment given declining profitability.
  4. Asked about the competitive landscape for premium whisky brands in India.

Market Trends & Consumer Behavior

  1. Asked about the impact of potential US ethanol imports on the Biofuel business.
  2. Inquired about the government's molasses reservation policy for Country Liquor in Uttar Pradesh.
  3. Questioned the current unexecuted order book in the Biofuel segment and traction from OMCs.
  4. Asked about the rationale for margin expansion in Potable Spirits, driven by premium brands.

Financial Highlights

  1. Inquired about the segmental bifurcation of the INR 1,400 crores long-term debt.
  2. Asked about the current cost of debt and expected interest rate reduction post-repayment.
  3. Questioned if a credit rating re-rating is expected after the INR 600 crores debt repayment.
  4. Sought details on CAPEX plans for the next couple of years and capacity to support growth.

Product Composition

  1. Asked for details on the contribution of the NSU segment (new performance chemicals) going forward.
  2. Inquired about the strategy for branded nutraceuticals, including certifications and market entry.
  3. Questioned the gross margin profiles of Amrut brands versus legacy brands.
  4. Asked about the strategy for market expansion in Kerala for the liquor business.

Strategic Considerations

  1. Asked about the long-term strategy for driving growth in new value-added chemicals.
  2. Inquired about the company's approach to exploring advanced biofuels and chemical derivatives of ethanol.
  3. Sought clarification on the exclusivity and financial contours of the Amrut partnership.
  4. Asked about the strategy for building a branded portfolio in the Ennature Bio Pharma segment.